{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-05-19",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "submissions": [
        {
          "submission_type": "SUPPL",
          "submission_number": "2",
          "submission_status": "AP",
          "submission_status_date": "20230615",
          "review_priority": "PRIORITY",
          "submission_class_code": "EFFICACY",
          "submission_class_code_description": "Efficacy",
          "application_docs": [
            {
              "id": "74508",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205551s31,215413s02lbl.pdf",
              "date": "20230616",
              "type": "Label"
            },
            {
              "id": "74521",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/215413Orig1s002;205551Orig1s031ltr.pdf",
              "date": "20230616",
              "type": "Letter"
            }
          ]
        },
        {
          "submission_type": "ORIG",
          "submission_number": "1",
          "submission_status": "AP",
          "submission_status_date": "20220330",
          "review_priority": "PRIORITY",
          "submission_class_code": "TYPE 3",
          "submission_class_code_description": "Type 3 - New Dosage Form",
          "application_docs": [
            {
              "id": "70670",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215413Orig1s000ltr.pdf",
              "date": "20220331",
              "type": "Letter"
            },
            {
              "id": "70675",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215413s000lbl.pdf",
              "date": "20220331",
              "type": "Label"
            },
            {
              "id": "71048",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215413Orig1s000TOC.html",
              "date": "20220512",
              "type": "Review"
            }
          ]
        },
        {
          "submission_type": "SUPPL",
          "submission_number": "5",
          "submission_status": "AP",
          "submission_status_date": "20251028",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "application_docs": [
            {
              "id": "83968",
              "url": "http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215413s005lbl.pdf",
              "date": "20251029",
              "type": "Label"
            },
            {
              "id": "83969",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215413s005lbl.pdf#page=56",
              "date": "20251029",
              "type": "Medication Guide"
            },
            {
              "id": "83985",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/205551Orig1s034;215413Orig1s005ltr.pdf",
              "date": "20251029",
              "type": "Letter"
            }
          ]
        },
        {
          "submission_type": "SUPPL",
          "submission_number": "3",
          "submission_status": "AP",
          "submission_status_date": "20240418",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "application_docs": [
            {
              "id": "78165",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205551s032,215413s003lbl.pdf",
              "date": "20240419",
              "type": "Label"
            }
          ]
        },
        {
          "submission_type": "SUPPL",
          "submission_number": "1",
          "submission_status": "AP",
          "submission_status_date": "20221007",
          "review_priority": "STANDARD",
          "submission_class_code": "LABELING",
          "submission_class_code_description": "Labeling",
          "application_docs": [
            {
              "id": "72288",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/205551Orig1s029,215413Orig1s001ltr.pdf",
              "date": "20221011",
              "type": "Letter"
            },
            {
              "id": "72302",
              "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205551s029,215413s001lbl.pdf",
              "date": "20221011",
              "type": "Label"
            }
          ]
        }
      ],
      "application_number": "NDA215413",
      "sponsor_name": "VIIV HLTHCARE",
      "openfda": {
        "application_number": [
          "NDA215413"
        ],
        "brand_name": [
          "TRIUMEQ PD"
        ],
        "generic_name": [
          "ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE"
        ],
        "manufacturer_name": [
          "ViiV Healthcare Company"
        ],
        "product_ndc": [
          "49702-258",
          "49702-231"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "rxcui": [
          "1546888",
          "1546894",
          "2598348",
          "2598352"
        ],
        "spl_id": [
          "4018a8c7-db0d-481e-b50a-a469ba32ec4b"
        ],
        "spl_set_id": [
          "2997739a-aa91-42aa-a206-a70e2db7b84f"
        ],
        "package_ndc": [
          "49702-231-13",
          "49702-258-37",
          "49702-272-59"
        ],
        "nui": [
          "N0000175656",
          "N0000175462",
          "N0000009947"
        ],
        "pharm_class_epc": [
          "Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]",
          "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"
        ],
        "pharm_class_moa": [
          "Nucleoside Reverse Transcriptase Inhibitors [MoA]"
        ],
        "unii": [
          "J220T4J9Q2",
          "1Q1V9V5WYQ",
          "2T8Q726O95"
        ]
      },
      "products": [
        {
          "product_number": "001",
          "reference_drug": "Yes",
          "brand_name": "TRIUMEQ PD",
          "active_ingredients": [
            {
              "name": "ABACAVIR SULFATE",
              "strength": "EQ 60MG BASE"
            },
            {
              "name": "DOLUTEGRAVIR SODIUM",
              "strength": "EQ 5MG BASE"
            },
            {
              "name": "LAMIVUDINE",
              "strength": "30MG"
            }
          ],
          "reference_standard": "Yes",
          "dosage_form": "TABLET, FOR SUSPENSION",
          "route": "ORAL",
          "marketing_status": "Prescription"
        }
      ]
    }
  ]
}